Business Description
VolitionRX Ltd
NAICS : 339112
SIC : 5047
ISIN : US9286611077
Total Employee Number:
75Description
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | -3.54 | |||||
Debt-to-Equity | -0.37 | |||||
Debt-to-EBITDA | -0.57 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -48.87 | |||||
Beneish M-Score | -3.68 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 42.8 | |||||
3-Year EBITDA Growth Rate | 29.5 | |||||
3-Year EPS without NRI Growth Rate | 26.1 | |||||
3-Year FCF Growth Rate | 15.3 | |||||
3-Year Book Growth Rate | -82.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 47.49 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 149.94 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.89 | |||||
9-Day RSI | 41.55 | |||||
14-Day RSI | 38.32 | |||||
3-1 Month Momentum % | -58.08 | |||||
6-1 Month Momentum % | -79.13 | |||||
12-1 Month Momentum % | -89.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.33 | |||||
Quick Ratio | 0.33 | |||||
Cash Ratio | 0.23 | |||||
Days Sales Outstanding | 37.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.5 | |||||
Shareholder Yield % | -118.49 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -853.61 | |||||
Net Margin % | -997.49 | |||||
EBITDA Margin % | -835.32 | |||||
FCF Margin % | -841.97 | |||||
OCF Margin % | -838.04 | |||||
ROA % | -310.49 | |||||
ROIC % | -243.64 | |||||
3-Year ROIIC % | -120.55 | |||||
ROC (Joel Greenblatt) % | -461.33 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.28 | |||||
EV-to-EBIT | -1.07 | |||||
EV-to-EBITDA | -1.13 | |||||
EV-to-Revenue | 9.45 | |||||
EV-to-Forward-Revenue | 9.51 | |||||
EV-to-FCF | -1.12 | |||||
Price-to-GF-Value | 0.06 | |||||
Earnings Yield (Greenblatt) % | -93.46 | |||||
FCF Yield % | -129.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:VNRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VolitionRX Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.466 | ||
| EPS (TTM) ($) | -4.17 | ||
| Beta | 1.1282 | ||
| 3-Year Sharpe Ratio | -0.95 | ||
| 3-Year Sortino Ratio | -1.16 | ||
| Volatility % | 66.47 | ||
| 14-Day RSI | 38.32 | ||
| 14-Day ATR ($) | 0.16277 | ||
| 20-Day SMA ($) | 1.35725 | ||
| 12-1 Month Momentum % | -89.78 | ||
| 52-Week Range ($) | 1.17 - 16 | ||
| Shares Outstanding (Mil) | 11.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VolitionRX Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VolitionRX Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:30 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 123 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 32 days | ||
| General meeting for 2026 | 2026-07-17 14:30 | In 5 days | ||
| First quarter earnings conference call for 2026 | 2026-05-15 08:30 | 2.20 (-0.90%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.20 (-0.90%) | ||
| 0.05:1 Stock Split | 2026-04-28 | 2.72 (-0.73%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-01 08:30 | 4.04 (+6.32%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-01 | 4.04 (+6.32%) |
Show
Entries
VolitionRX Ltd Frequently Asked Questions
What is VolitionRX Ltd(VNRX)'s stock price today?
The current price of VNRX is $1.35. The 52 week high of VNRX is $16.00 and 52 week low is $1.17.
When is next earnings date of VolitionRX Ltd(VNRX)?
The next earnings date of VolitionRX Ltd(VNRX) is 2026-08-14 Est..
Does VolitionRX Ltd(VNRX) pay dividends? If so, how much?
VolitionRX Ltd(VNRX) does not pay dividend.
Guru Commentaries on AMEX:VNRX
No articles.
Press Release
Articles on VolitionRX Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers